CDK4/6 转移性环境中的抑制:我们将走向何方?
Elizabeth Sakach1, Merve Keskinkilic2, Sarah Wood3
1Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA. esakach@emory.edu.
Current treatment options in oncology
|June 14, 2023
概括
激素受体阳性,HER2阴性转移性乳腺癌的治疗已经在CDK4/6抑制剂的治疗中取得了显著进展. 现在的研究集中在这些疗法进展后的最佳策略上,以改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 医疗治疗 医疗治疗
背景情况:
- 激素受体阳性 (HR+),人体表皮生长因子受体2-阴性 (HER2-) 转移性乳腺癌 (MBC) 是最常见的亚型.
- 转移性乳腺癌的显著预后改善归因于分子向疗法.
- 循环素依赖性激酶4/6抑制剂 (CDK4/6i) 已经彻底改变了HR+/HER2- MBC的治疗环境.
研究的目的:
- 审查HR+/HER2-MBC目前的治疗模式.
- 讨论在CDK4/6抑制剂的进展后不断发展的治疗策略.
- 探索新的组合疗法和CDK4/6i失败后的治疗顺序.
主要方法:
- 最近的临床试验和专家意见的文献综述.
- 对HR+/HER2-MBC患者的治疗结果和生存数据的分析.
- 讨论新兴的治疗目标和个性化医疗方法.
主要成果:
- CDK4/6抑制剂在整体存活率和生活质量方面表现出显著的改善.
- CDK4/6抑制剂延迟了HR+/HER2- MBC中开始化疗的需要.
- 在CDK4/6i进展后最佳的治疗顺序仍然是一个活跃的研究领域.
结论:
- HR+/HER2-MBC的管理正在转向个性化,多方面的治疗策略.
- 未来的研究应该专注于新的组合和顺序疗法,以克服对CDK4/6抑制剂的耐药性.
- 针对性治疗的持续进步有望进一步改善转移性乳腺癌患者的治疗结果.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Positive Regulator Molecules
5.5K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.5K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K


